Pharsight

Valtoco is owned by Neurelis Inc.

Valtoco contains Diazepam.

Valtoco has a total of 5 drug patents out of which 0 drug patents have expired.

Valtoco was authorised for market use on 10 January, 2020.

Valtoco is available in spray;nasal dosage forms.

Valtoco can be used as nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older.

The generics of Valtoco are possible to be released after 27 March, 2029.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265402	NEURELIS INC	Absorption enhancers for drug administration	May, 2025 (1 year, 11 months from now)
US9642913	NEURELIS INC	Pharmaceutical composition including alkyl glycoside and an anti-seizure agent	May, 2025 (1 year, 11 months from now)
US8927497	NEURELIS INC	Absorption enhancers for intranasal administration	Jul, 2025 (2 years from now)
US8895546	NEURELIS INC	Administration of benzodiazepine compositions	Mar, 2029 (5 years from now)
US11241414	NEURELIS INC	Administration of benzodiazepine compositions	Mar, 2029 (5 years from now)

Do you want to check out VALTOCO patents from before 2022?

Exclusivity	Exclusivity Expiration
New Product (NP)	Jan 10, 2023
Orphan Drug Exclusivity (ODE)	Jan 10, 2027

Drugs and Companies using DIAZEPAM ingredient

Market Authorisation Date: 10 January, 2020

Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older

Dosage: SPRAY;NASAL